Objectives: The long-term prognostic value (> 5 years) of elevated cardiac biomarkers after elective coronary angioplasty is yet not clear. Most previous studies have included high risk, unstable patients and with conflicting results. The aim of this study was to determine the prognostic value of CK-MB mass vs. the cardiac troponins (values ≥ 3 times the reference) after elective angioplasty in low-risk patients with stable angina.
Methods: A total of 202 consecutive patients were included in the final analysis. Patients with elevated values at baseline, and those suffering an acute coronary syndrome < 1 month before the time of inclusion, were excluded. Blood samples were drawn just before, 1-3 hours and 4-8 hours after the procedure and the next morning. Using a cutoff value of three times the reference, patients with high and low values (= controls) of CK-MB mass, cardiac troponin T (TnT) and troponin I (TnI) were compared. No patient developed new Q-waves on ECG. The median follow-up time was 82 months equalising 1600 patient years.
Results: None of the patients died during the procedure or within the first 30 days after angioplasty, confirming a low risk cohort. There was an increasingly number of patients with levels ≥ 3 times the reference post procedure in TnT (10.4%) and TnI (16.8%) vs. CK-MB (6.9%). All cause mortality, readmission for acute coronary syndromes and target lesion revascularisation were more frequent in patients with high CK-MB, 42.9% vs. 22.3 %, p = 0.05 (log-rank test). Corresponding values for TnT were 33.3% vs. 22.7%, p = 0.22. In the TnI patients, there were more adverse events in controls vs. the high group, 25.0% vs. 17.6%, p = 0.34.
Conclusions: CK-MB mass values ≥ 3 times, contrary to the cardiac troponins, predicts worse long-term event-free survival after elective angioplasty in low-risk patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/14017431.2011.563864 | DOI Listing |
bioRxiv
December 2024
Lester and Sue Smith Breast Center and Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Combination chemotherapy remains essential for clinical management of triple-negative breast cancer (TNBC). Consequently, responses to individual agents cannot be easily delineated at the single patient level, even though some patients might not require all drugs in the combination. Herein, we conduct multi-omic analyses of orthotopic TNBC patient-derived xenografts (PDXs) treated with single agent carboplatin, docetaxel, or the combination.
View Article and Find Full Text PDFAm J Transl Res
November 2024
Acupuncture and Tuina College, Nanjing University of Chinese Medicine Nanjing 210023, Jiangsu, China.
Objective: To explore the influence of obesity on microvascular obstruction (MVO) and myocardial area at risk (AAR) in patients with ST-segment elevation myocardial infarction (STEMI).
Methods: A retrospective analysis was performed on patients with first-episode STEMI hospitalized at Nanjing University of Traditional Chinese Medicine between May 2020 and May 2022. Patients were categorized into normal weight, overweight, and obese groups based on their body mass index (BMI).
Int J Obes (Lond)
December 2024
Division of Pediatric Endocrinology and Diabetology, University Children's Hospital, University of Zurich, Zurich, Switzerland.
J Tradit Chin Med
December 2024
Institute of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Biomark Med
December 2024
Department of Cardiology, Wugang People's Hospital, Wugang, Hunan, China.
Objective: This study investigates the predictive value of CK-MB in treating acute myocardial infarction (AMI) with urokinase combined with low molecular weight heparin (LMWH) calcium.
Methods: AMI patients treated at our hospital from April 2020 to August 2022 were included in this prospective, multi-center cohort study. Patients were randomly assigned to a urokinase group or a combined treatment group (urokinase plus LMWH).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!